



ASX Announcement

13 June 2024

Receipt of Research & Development Tax Incentive

Melbourne, Australia, 13 June 2024 - Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company"), is pleased to confirm the receipt of \$1.07 million for the year ended 31 December 2023 under the Australian Government's Research and Development ("R&D") Tax Incentive Scheme.

The R&D Tax Incentive Scheme is an Australian Government program developed to assist businesses recover some of the costs of undertaking research and development.

The receipt of these funds confirms the Company's significant and ongoing commitment to the development of differentiated cannabinoid formulations for pharmaceutical registration. The funds will be used to support the ongoing Phase III insomnia clinical trial, Company operations, and to advance our commercialisation strategy in order to bring innovative medicines to patients globally.

For enquiries, please contact

Ms Melanie Leydin
Company Secretary
Avecho Biotechnology Limited
+61 3 9002 5000

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

About Avecho

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of livestock.

See more here - avecho.com.au